Avicanna Announces Resignation of Director
12 November 2021 - 1:30AM
Avicanna Inc. ("
Avicanna" or the
"
Company") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN),
a biopharmaceutical company focused on the development,
manufacturing, and commercialization of organic and sustainable
plant-derived cannabinoid-based products announces that Flavio Jose
Zaclis has resigned as a director of the Company effective
immediately for personal reasons.
Aras Azadian, Chief Executive Officer, commented
“We wanted to express our gratitude to Flavio for stepping into the
role at a critical time for the company and helping us pave the
path for our next stage of growth and evolution. We look forward to
having his continued support and guidance as an advisor to the
company.”
Mr. Zaclis commented: "I am very happy to have
been able to support the management during a transitional period
and impressed by what has been accomplished so far. I am very
optimistic about the future and the evolution of the Company and
its business models. I will continue to support Avicanna during its
next phase of growth especially in the Brazilian market where they
are establishing a strong footprint."
About Avicanna
Avicanna is a Canadian commercial-stage
biopharmaceutical company established in cannabinoid research,
development, and evidence-based products for the global consumer,
as well as medical and pharmaceutical market segments. In leading
global cannabinoid advancements, Avicanna conducts most of its
research in Canada at its R&D headquarters in the Johnson &
Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS
Discovery District. The Company actively collaborates with leading
Canadian academic and medical institutions. Avicanna has
established an industry-leading scientific platform including
advanced R&D and clinical development which has led to the
commercialization of over twenty products across four main market
segments:
- Medical
Cannabis & Wellness Products: Marketed under the RHO
Phyto™ brand, or Magisterial Preparations, these medical and
wellness products are an advanced line of pharmaceutical-grade
cannabis products containing varying ratios of cannabidiol (“CBD”)
and tetrahydrocannabinol (“THC”). The product portfolio contains a
full formulary of products including oral, sublingual, topical, and
transdermal deliveries that have controlled dosing, enhanced
absorption and stability studies supported by pre-clinical data.
The advanced formulary is marketed with consumer, patient and
medical community education and training. Avicanna’s medical and
wellness product portfolio also forms the foundation of the
Company’s pharmaceutical pipeline with the contribution of the
formulations that form the basis of the products as well as the
data generated from sales and participation of the products in real
world evidence studies.
- CBD
Derma-Cosmetic Products: Marketed under the Pura H&W™
or Pura Earth™ brands, these registered, clinically tested,
dermacosmetic products include a portfolio of functional CBD
topical products.
-
Pharmaceuticals: Leveraging Avicanna’s scientific
platform, vertical integration, and real-world evidence, Avicanna
has created a pipeline of patent-pending drug candidates which are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates
provide solutions for unmet medical needs in the areas of
dermatology, chronic pain, and various neurological disorders.
Avicanna’s first pharmaceutical preparation (TruneroxTM) is in the
drug registration stage in South America.
- Cannabis
Raw Materials, Seeds, and Bulk Formulations: Marketed
under the Aureus™ brand, the Company’s raw material business has
successfully completed sales to 11 countries. Aureus offers
cannabis dried flower, standardized seeds, full spectrum extracts,
and cannabinoid distillates, isolated cannabinoids (CBD, THC,
cannabigerol (“CBG”) and other rare cannabinoids), and bulk
formulations derived from hemp and cannabis cultivars through its
sustainable, economical, and industrial-scale subsidiaries based in
Colombia. The majority of the Aureus products are produced at Santa
Marta Golden Hemp S.A.S. (“SMGH”), the Company’s majority-owned
subsidiary, which is also Good Agricultural and Collection
Practices (“GACP”) certified and has United States Department of
Agriculture (“USDA”) National Organic Program certification for its
hemp cultivar.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, or contact Ivana Maric by email at
info@avicanna.com.
The Company posts updates through videos from
the official company YouTube channel
https://www.youtube.com/channel/UCFXPBGdKSxOUOf_VZoSFSUA.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release includes statements containing
certain "forward-looking information" within the meaning of
applicable securities law ("forward-looking statements").
Forward-looking statements are frequently characterized by words
such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur. These forward-looking
statements are only predictions. Various assumptions were used in
drawing the conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions, estimates and
assumptions of management in light of management's experience and
perception of historical trends, current conditions and expected
developments at the date the statements are made, such as current
and future market conditions, the current and future regulatory
environment and future approvals and permits. Forward-looking
statements are subject to a variety of risks, uncertainties and
other factors that management believes to be relevant and
reasonable in the circumstances could cause actual events, results,
level of activity, performance, prospects, opportunities or
achievements to differ materially from those projected in the
forward-looking statements, including general business and economic
conditions, changes in laws and regulations, product demand,
changes in prices of required commodities, competition, the effects
of and responses to the COVID-19 pandemic and other risks,
uncertainties and factors set out under the heading “Risk Factors”
in the Company’s annual information form dated April 15, 2020 (the
“AIF”) and filed with Canadian securities
regulators available on the Company’s issuer profile on SEDAR at
www.sedar.com. The Company cautions that the list of risks,
uncertainties and other factors described in the AIF is not
exhaustive and other factors could also adversely affect its
results. Readers are urged to consider the risks, uncertainties and
assumptions carefully in evaluating the forward-looking statements
and are cautioned not to place undue reliance on such information.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable securities
laws.
Avicanna (TSX:AVCN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Avicanna (TSX:AVCN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024